GlobalData

The immune thrombocytopenia (ITP) market across the seven major countries of the US, France, Gern

The company's latest report states that the ITP space will see reasonable growth at the beginn

From 2023, however, market value will start declining due to the patent expiration and subsequent gen

Fenix Leung, DPhil, Healthcare Analyst for GlobalData, explains: "Companies are looking into drugs wi

GlobalData has determined that the ITP market has a weak pipeline. Since the approval of Nplate and

Avatrombopag has encountered difficulties in clinical trial participant recruitment, and GlobalData belie

Leung concludes: "Despite the harsh market environment, GlobalData sees ample opportunity for phar

"Ultimately, the ITP market is looking for curative therapies that offer long-term remission for patients, a